BRIEF-Novan Focuses Strategic Direction, Announces Restructuring

Reuters2023-06-01

May 31 (Reuters) - Novan Inc :

* NOVAN FOCUSES STRATEGIC DIRECTION AND ANNOUNCES RESTRUCTURING

* NOVAN INC - DIRECTING RESOURCES ON POTENTIAL APPROVAL OF BERDAZIMER GEL, 10.3% (SB206) FOR MOLLUSCUM CONTAGIOSUM

* NOVAN INC - PROCESS TO EXPLORE A SALE OR OUT-LICENSE OF COMMERCIAL ASSETS OR OTHER BUSINESS TRANSACTION CONTINUES

* NOVAN INC - CONTINUED PROGRESS TOWARD PDUFA GOAL DATE OF JANUARY 5, 2024, FOR BERDAZIMER GEL, 10.3%

* NOVAN INC - CONTINUED PROGRESS TOWARD PDUFA GOAL DATE OF JANUARY 5, 2024, FOR BERDAZIMER GEL, 10.3%

* NOVAN INC - WILL IMMEDIATELY REDUCE CERTAIN OF ITS OPERATING EXPENSES CURRENTLY SUPPORTING ITS COMMERCIAL OPERATIONS.

* NOVAN - TO SELL AND DISTRIBUTE COMMERCIAL PRODUCTS, INCUR CERTAIN RELATED EXPENSES ASSOCIATED WITH RHOFADE, WYNZORA, MINOLIRA, CLODERM IN U.S.

* NOVAN - EXISTING CASH AND CASH EQUIVALENTS AS OF MARCH 31 TO PROVIDE CO WITH LIQUIDITY TO FUND PLANNED OPERATIONS INTO LATE JUNE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2340101642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-06-01 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2340101642","market":"us","top_or_hot":-1,"title":"BRIEF-Novan Focuses Strategic Direction, Announces Restructuring","media":"Reuters","content":"<html><body><p>May 31 (Reuters) - Novan Inc   :</p><p>   * NOVAN FOCUSES STRATEGIC DIRECTION AND ANNOUNCES RESTRUCTURING</p><p>   * NOVAN INC - DIRECTING RESOURCES ON POTENTIAL APPROVAL OF BERDAZIMER GEL, 10.3% (SB206) FOR MOLLUSCUM CONTAGIOSUM</p><p>   * NOVAN INC - PROCESS TO EXPLORE A SALE OR OUT-LICENSE OF COMMERCIAL ASSETS OR OTHER BUSINESS TRANSACTION CONTINUES</p><p>   * NOVAN INC - CONTINUED PROGRESS TOWARD PDUFA GOAL DATE OF JANUARY 5, 2024, FOR BERDAZIMER GEL, 10.3%</p><p>   * NOVAN INC - CONTINUED PROGRESS TOWARD PDUFA GOAL DATE OF JANUARY 5, 2024, FOR BERDAZIMER GEL, 10.3%</p><p>   * NOVAN INC - WILL IMMEDIATELY REDUCE CERTAIN OF ITS OPERATING EXPENSES CURRENTLY SUPPORTING ITS COMMERCIAL OPERATIONS.</p><p>   * NOVAN - TO SELL AND DISTRIBUTE COMMERCIAL PRODUCTS, INCUR CERTAIN RELATED EXPENSES ASSOCIATED WITH RHOFADE, WYNZORA, MINOLIRA, CLODERM IN U.S.</p><p>   * NOVAN - EXISTING CASH AND CASH EQUIVALENTS AS OF MARCH 31 TO PROVIDE CO WITH LIQUIDITY TO FUND PLANNED OPERATIONS INTO LATE JUNE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Novan Focuses Strategic Direction, Announces Restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Novan Focuses Strategic Direction, Announces Restructuring\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-01 05:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>May 31 (Reuters) - Novan Inc   :   * NOVAN FOCUSES STRATEGIC DIRECTION AND ANNOUNCES RESTRUCTURING   * NOVAN INC - DIRECTING RESOURCES ON POTENTIAL APPROVAL OF BERDAZIMER GEL, 10.3% (SB206) FOR ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2340101642","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2340101642","pubTimestamp":1685566950,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"May 31 (Reuters) - Novan Inc   :   * NOVAN FOCUSES STRATEGIC DIRECTION AND ANNOUNCES RESTRUCTURING  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"简介-Novan聚焦战略方向，宣布重组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NOVN":0.9},"content_text":"May 31 (Reuters) - Novan Inc   :   * NOVAN FOCUSES STRATEGIC DIRECTION AND ANNOUNCES RESTRUCTURING   * NOVAN INC - DIRECTING RESOURCES ON POTENTIAL APPROVAL OF BERDAZIMER GEL, 10.3% (SB206) FOR MOLLUSCUM CONTAGIOSUM   * NOVAN INC - PROCESS TO EXPLORE A SALE OR OUT-LICENSE OF COMMERCIAL ASSETS OR OTHER BUSINESS TRANSACTION CONTINUES   * NOVAN INC - CONTINUED PROGRESS TOWARD PDUFA GOAL DATE OF JANUARY 5, 2024, FOR BERDAZIMER GEL, 10.3%   * NOVAN INC - CONTINUED PROGRESS TOWARD PDUFA GOAL DATE OF JANUARY 5, 2024, FOR BERDAZIMER GEL, 10.3%   * NOVAN INC - WILL IMMEDIATELY REDUCE CERTAIN OF ITS OPERATING EXPENSES CURRENTLY SUPPORTING ITS COMMERCIAL OPERATIONS.   * NOVAN - TO SELL AND DISTRIBUTE COMMERCIAL PRODUCTS, INCUR CERTAIN RELATED EXPENSES ASSOCIATED WITH RHOFADE, WYNZORA, MINOLIRA, CLODERM IN U.S.   * NOVAN - EXISTING CASH AND CASH EQUIVALENTS AS OF MARCH 31 TO PROVIDE CO WITH LIQUIDITY TO FUND PLANNED OPERATIONS INTO LATE JUNESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2340101642"}